<qa>  What is the primary time point for the endpoints of Phases 1 and 2?All patients who were randomly assigned to treatment groups and had at least one post-baseline assessment will be included in the efficacy analysis. The primary time points will be the endpoints of Phases 1 and 2 i.e. the last available observation during Phases 1 and 2. The primary comparison will be between the lamotrigine sodium valproate groups. The analysis of covariance model will be used to test differences between treatments at endpoint. The model will include factors for treatment, and baseline scores on MRS and HRDS as a covariate. MRS scores at all time points will be analyzed jointly by means of repeated measures model. HRDS scores will be analyzed in the same way as MRS scores. Treatment over time will be used as a factor in the model. Gehans generalized Wilcoxon test will be used to evaluate differences in time to discontinuation ref from Sachs, and Van Elteren test will be used to evaluate differences in the CGI scores ref from Sachs. 